FDA ends GLP-1 compounding for semaglutide, t...

Rural and small healthcare entities face the same cyber threats as the nation's largest health systems, but often lack the tools to combat them in the same way. From funding scarcity to workforce shortages, rural healthcare organizations must balance the need for an effective cyb ...  Show more

Revenue cycle management is rife with data issues and automatable processes--making it ripe for AI implementation. How can providers use AI tools to reduce their revenue cycle management workload? Featuring: Jacqueline LaPointe, executive editor, lead editor on Rev Cycle Manageme ...  Show more

STAT's Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI drug development com ...  Show more

Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original ...

In this episode of the Dr. Gabrielle Lyon Show, we dive deep into the world of compounding pharmacies and the transformative power of anabolic steroids with special guest Shaun Noorian, founder of Empower Pharmacy, one of the largest compounding pharmacies in the U.S.Join us as S ...  Show more

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.

Why GLP-1 Drugs Are in Demand